NASDAQCommunication ServicesAdvertising AgenciesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SWAG yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Move towards sustained profitability | A primary condition in Stran & Co Inc's published investment case. The stated target is Positive net income by end of 2026. | Improving | Net income remains negative through FY26 | Net income: $309,000 FY2026-Q2; GAAP. Published target: Positive net income by end of 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 2026309,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
SWAG is a high-risk, loss-making business showing early signs of a turnaround, rather than an established durable compounder. Its long-term thesis is intact, though confidence has eased from high to medium and the evidence base is still limited.
The valuation picture is mixed: the evidence labels SWAG cheap versus peers, but also shows a 20% premium to peers and a negative expectations gap. Model confidence is low, so the market’s assumptions are difficult to pin down; the priced-in tag is justified, with low fragility.
Near-term results have improved: revenue rose from $28.7 million to $31.2 million year over year, while net income moved from a small loss to a profit. Management’s goal of sustained profitable growth in 2026 is on track, but acquisition benefits are not yet quantified and the next earnings report carries elevated miss risk.
The multi-year thesis depends on SWAG sustaining profitable growth, showing clearer benefits from acquisitions, and extending new client agreements into recurring business. Near term, a guidance cut would be a meaningful setback; rate cuts or continued strong results from sector peers could support the sector backdrop.
Over the next 1 to 3 years, SWAG offers an early profitability-improvement story, but high risk and incomplete proof of acquisition and client growth keep the thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 1 of 3 supplied quarters. Management reported: ““We delivered $31.2 million in revenue, up 8.9% year-over-year, alongside a gross margin of 30.9%, more than 100 basis points above the prior year period, and EBITDA of $1.0 million compared to EBITDA of $(0.2) million for Q1 2025.” ““Looking ahead, we believe 2026 is shaping up to be a year of sustained, profitable growth for Stran.”
Sustained revenue growth in 2026 | A primary condition in Stran & Co Inc's published investment case. The stated target is >=5% YoY revenue growth in 2026. | Intact | YoY revenue growth falls below 5% in FY26 | Revenue growth: 2.4% FY2026-Q2; GAAP. Published target: >=5% YoY revenue growth in 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 20262.397397 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: ““We delivered $31.2 million in revenue, up 8.9% year-over-year, alongside a gross margin of 30.9%, more than 100 basis points above the prior year period, and EBITDA of $1.0 million compared to EBITDA of $(0.2) million for Q1 2025.” ““Looking ahead, we believe 2026 is shaping up to be a year of sustained, profitable growth for Stran.” Delivery assessment Nov 4, 2026 |
Completion of strategic acquisitions | A supporting condition in Stran & Co Inc's published investment case. The stated target is Complete at least 2 strategic acquisitions in 2026. | Intact | No strategic acquisitions completed in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Valuation multiples normalize towards peers | The stock trades cheap versus peers despite high risk. | Intact | PE remains above 100 beyond 2027 without profit growth | P/E (TTM): 436.67x As of 2026-11-04; trailing twelve months. The target timing and basis require a separate assessment. Nov 4, 2026436.6667 ratio · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.